FDA grants accelerated approval to sacituzumab govitecan for advanced urothelial cancer
UPDATE: On November 22, 2024, the FDA announced the final withdrawal of the approval of sacituzumab govitecan-hziy (Trodelvy) for adult patients with locally advanced or metastatic urothelial cancer (mUC) who previously received a platinum-containing …